Last reviewed · How we verify

Telmisartan plus Metformin — Competitive Intelligence Brief

Telmisartan plus Metformin (Telmisartan plus Metformin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ARB + Biguanide combination. Area: Cardiovascular / Endocrinology.

marketed ARB + Biguanide combination Angiotensin II type 1 receptor (AT1R); mitochondrial glycerophosphate dehydrogenase Cardiovascular / Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Telmisartan plus Metformin (Telmisartan plus Metformin) — Third Military Medical University. Telmisartan blocks angiotensin II receptors to lower blood pressure, while metformin reduces hepatic glucose production and improves insulin sensitivity to control blood sugar.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Telmisartan plus Metformin TARGET Telmisartan plus Metformin Third Military Medical University marketed ARB + Biguanide combination Angiotensin II type 1 receptor (AT1R); mitochondrial glycerophosphate dehydrogenase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ARB + Biguanide combination class)

  1. Third Military Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Telmisartan plus Metformin — Competitive Intelligence Brief. https://druglandscape.com/ci/telmisartan-plus-metformin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: